Perindopril Erbumine
NDC Package 68180-235-01

11-digit billing NDC: 68180023501

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Perindopril Erbumine is stable Coronary Artery DiseasePerindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Marketed by Lupin Pharmaceuticals, Inc, this product is identified by NDC 68180-235 and is authorized under FDA application ANDA078263.

Identification & Billing

NDC Package Code
68180-235-01
Package Description
100 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
68180023501
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Perindopril Erbumine
Dosage Form
-
Usage Information
Stable Coronary Artery DiseasePerindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS.) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS: Head and Neck Angioedema.)

Regulatory & Marketing

Labeler Name
Lupin Pharmaceuticals, Inc
FDA Application #
ANDA078263
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-15-2010
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68180-235-01 identifies a specific commercial package of 100 tablet in 1 bottle of Perindopril Erbumine, labeled by Lupin Pharmaceuticals, Inc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Lupin Pharmaceuticals, Inc on March 15, 2010. The current certification is valid through December 31, 2017.

How is this Lupin Pharmaceuticals, Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68180023501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68180-235-01
11-Digit CMS (5-4-2)
68180-0235-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.